ClinicalTrials.gg
RecruitingNCT07948070Updated Nov 19, 2026

A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer

A Phase 1/2 interventional study of GKPTZ-01 in Combination with Adjuvant Chemotherapy and GKPTZ-01 in Pancreatic Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Pancreatic Neoplasms by Tianjin Medical University Cancer Institute and Hospital — 19 open to participants now, 19 under way, 2 of them phase 3. Pancreatic Neoplasms · Tianjin Medical University Cancer Institute and Hospital.

Planned enrollment
10th of 24
40 · median 32
Started
2026
with 6 others
Phase 1/2
4 of 27
4 open now
Primary completion
2028-07
later than 17 of 18 live
Registered
27th of 27
by date

Among the 27 studies in Pancreatic Neoplasms by Tianjin Medical University Cancer Institute and Hospital, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2026, is one of 4 in phase 1/2, reaches primary completion later than 17 of the 18 other live ones, and was the 27th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

19 of the 27 studies in Pancreatic Neoplasms by Tianjin Medical University Cancer Institute and Hospital are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pancreatic Neoplasms by Tianjin Medical University Cancer Institute and Hospital, or all of them as a file.
02

Study summary

A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Adjuvant Therapy
  • Advanced Pancreatic Cancer
  • Refractory
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Form (ICF) .
  • Aged 18 to 70 years (inclusive) at the time of signing the ICF.
  • Cytology or pathology confirmed Patients with pancreatic tumors.

Cohort 1:

  • The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
  • chemotherapy completed, as determined by the investigator.

Cohort 2:

  • Disease progression after prior standard systemic antitumor therapy for the current disease stage;
  • Inability to continue standard therapy due to and intolerable toxicities, as determined by the investigator, during prior standard treatment;
  • No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
  • For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.

Cohort 3:

  • Patients receiving standard chemotherapy regimens include, but are not limited to:

    • the oFOLFIRINOX regimen;
    • gemcitabine combined with nab-paclitaxel; or
    • other standard or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
  • Patients receiving targeted therapy must meet all the following criteria:

    • Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, alterations, NTRK fusions, or MSI-H/dMMR status);
    • The investigator determines that no exist for the proposed targeted therapy.
  • score of 0 \~1 .
  • Expected survival time is more than 12 weeks.
  • Negative blood pregnancy test for females of is required.

Exclusion criteria

Exclusion Criteria:

  • Patients with central nervous system (CNS) , , or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
  • History of bone marrow or organ transplantation;
  • History of other primary ;
  • surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; virus (HCV) antibody positive and HCV RNA positive; (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
  • Patients with a known allergy to any component of the study drugs.
  • History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
  • Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
  • Diagnosis of active disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
  • thyroid dysfunction as assessed by the investigator.
  • Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
  • Clinically significant cardiovascular diseases.
  • Insufficient bone marrow reserve or insufficient organ function.
  • Female subjects who are pregnant or breastfeeding.
  • Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
  • The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Drug: GKPTZ-01 in Combination with Adjuvant Chemotherapy

  • Experimental
    Cohort 2

    Drug: GKPTZ-01

  • Experimental
    Cohort 3

    Drug: GKPTZ-01 in Combination with Chemotherapy or Targeted Therapy

Interventions

  • DrugGKPTZ-01 in Combination with Adjuvant Chemotherapy

    Combination with Adjuvant Chemotherapy

  • DrugGKPTZ-01

    GKPTZ-01

  • DrugGKPTZ-01 in Combination with Chemotherapy or Targeted Therapy

    Combination with Chemotherapy or Targeted Therapy

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival

    6 months RFS(recurrence-free survival) rate(cohort 1)

    Time frame: 2 years

  2. Objective response rate

    Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3)

    Time frame: 2 years

Secondary outcomes

  1. Disease Control Rate(DCR)

    Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01

    Time frame: 2 years

  2. Duration of Response(DOR)

    Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier

    Time frame: 2 years

  3. Progression-free Survival(PFS)

    Time from GKPTZ-01 treatment to disease progression or death

    Time frame: 2 years

  4. Overall survival(OS)

    Time from GKPTZ-01 treatment to death

    Time frame: 2 years

  5. Adverse events

    The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events).

    Time frame: 2 years

  6. Patient Quality of Life

    EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30)

    Time frame: 2 years

Other outcomes

  1. Pharmacokinetic

    Levels of T-cell Receptor copies

    Time frame: 2 years

  2. Biomarker

    Concentration levels of serum cytokines, tumor markers

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2028, 25 months after the start.

Of 94 non-industry phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 95. This study's planned 25 months is below that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948070
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jun 2, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Hao Jihui
Contact
haojihui@tjmuch.com
+86-02223340123

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion